FGF18 as a prognostic and therapeutic biomarker in ovarian cancer

Journal of Clinical Investigation

Volumn 123, Issue 10, 2013, Pages 4435-4448

  Wei, Wei ^a   Mok, Samuel C ^b   Oliva, Esther ^a   Kim, Sung Hoon ^a,c   Mohapatra, Gayatry ^a   Birrer, Michael J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FGF18 PROTEIN; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; CD31 ANTIGEN; CYTOKINE; FIBROBLAST GROWTH FACTOR 18; TRANSCRIPTOME; TUMOR MARKER;

AMPLICON; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CAPILLARY DENSITY; CARCINOGENICITY; CELL CULTURE; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; POLARIZATION; PREDICTIVE VALUE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MICROVASCULATURE; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; CELL LINE, TUMOR; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; MICROVESSELS; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84885056979     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70625     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415-428.
3. Spentzos D, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700-4710.
4. Birrer MJ, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007;25(16):2281-2287.
5. Mok SC, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009;16(6):521-532.
6. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
7. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139-149.
8. Haque T, Nakada S, Hamdy RC. A review of FGF18: Its expression, signaling pathways and possible functions during embryogenesis and post-natal development. Histol Histopathol. 2007;22(1):97-105.
9. Antoine M, et al. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun. 2006;346(1):224-233.
10. Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol. 2007;302(1):80-91.
11. Franco-Montoya ML, et al. Profiling target genes of FGF18 in the postnatal mouse lung: possible relevance for alveolar development. Physiol Genomics. 2011;43(21):1226-1240.
12. Wu R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11(4):321-333.
13. Stany MP, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6(7):e21121.
14. Crum CP, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3-9.
15. Tone AA, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res. 2008;14(13):4067-4078.
16. Engler DA, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One. 2012;7(2):e30996.
17. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-129.
18. Zhang X, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281(23):15694- 15700.
19. Richmond A. Nf-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2(9):664-674.
20. Bieche I, et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer. 2007;14(4):1039-1052.
21. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
22. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
23. Robinson-Smith TM, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67(12):5708-5716.
24. Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med. 2009;100(5):357-370.
25. Reinhold MI, et al. FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem. 2004;279(37):38209-38219.
26. Acevedo VD, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559-571.
27. Wu J, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71(2):349-359.
28. White KL, et al. Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control. 2011;22(5):785-801.
29. Tsujimoto H, et al. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010;13(4):212-221.
30. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010;11(9):1133-1146.
31. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18(18):2195-2224.
32. Mantovani F, et al. NF-κB mediated transcriptional activation is enhanced by the architectural factor HMGI-C. Nucleic Acids Res. 1998;26(6):1433-1439.
33. Perrella MA, et al. High mobility group-I (Y) protein facilitates nuclear factor-kappaB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer. J Biol Chem. 1999;274(13):9045-9052.
34. Noro B, et al. Molecular dissection of the architectural transcription factor HMGA2. Biochemistry. 2003;42(15):4569-4577.
35. Busser B, et al. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119-131.
36. Fleming JM, et al. Paracrine interactions between primary human macrophages and human fibroblasts enhance murine mammary gland humanization in vivo. Breast Cancer Res. 2012;14(3)
37. Qian B, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One. 2009;4(8):e6562.
38. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011;13(5):393-405.
39. Yang G, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(44):16472-16477.
40. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.
41. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121(1):230-238.
42. Zaid TM, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, highgrade serous ovarian cancer. Clin Cancer Res. 2013;19(4):809-820.
43. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011;17(5):283-292.
44. Harding TC, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med. 2013;5(178):178ra39.
45. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36(2):169-180.